These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6212749)

  • 21. Mode of decrease of leukemic cells and leukocytes during neocarzinostatin treatment.
    Masaoka T; Hasegawa Y; Yoshitake J; Ueda T; Takubo T
    Cancer Treat Rep; 1977; 61(1):73-5. PubMed ID: 140763
    [No Abstract]   [Full Text] [Related]  

  • 22. [Reductive effect on ascites, of neocarzinostatin in patients with ovarian cancer].
    Takahashi K; Watanabe M; Kikuchi J; Kishi H; Saito K; Mouri H; Ikeno N; Endo H; Shima I; Morizuka T
    Gan To Kagaku Ryoho; 1988 May; 15(5):1777-81. PubMed ID: 2967052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Studies on the stability of antitumor protein, neocarzinostatin. II. Stability of injection of neocarzinostatin (author's transl)].
    Kono M; Ishii F; Haneda I; Koyama Y; Kikuchi M
    Jpn J Antibiot; 1974 Dec; 27(6):715-24. PubMed ID: 4282495
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in antitumor antibiotics.
    Umezawa H
    Antibiot Chemother (1971); 1978; 23():76-87. PubMed ID: 77145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic effects of perioperatively administered neocarzinostatin in renal cell carcinoma.
    Satake I; Tari K; Ohwada F; Saitoh T; Negishi T
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):809-16. PubMed ID: 2528598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neocarzinostatin (NSC 157365) a new cancerostatic compound.
    Legha SS; Von Hoff DD; Rozencweig M; Abraham D; Slavik M; Muggia M
    Oncology; 1976; 33(5-6):265-70. PubMed ID: 141012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electron microscopic observations on structures appearing in Trypanosoma gambiense after treatment with neocarzinostatin.
    Ono T; Nakabayashi T
    Biken J; 1976 Dec; 19(4):171-7. PubMed ID: 140680
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I study of neocarzinostatin in patients with acute leukemia.
    Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1978 Sep; 62(9):1363-5. PubMed ID: 150945
    [No Abstract]   [Full Text] [Related]  

  • 29. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein.
    Maeda H; Takeshita J; Kanamaru R; Sato H; Khatoh J; Sato H
    Gan; 1979 Oct; 70(5):601-6. PubMed ID: 160353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of internalization and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line, K562.
    Kohgo Y; Kondo H; Kato J; Sasaki K; Tsushima N; Nishisato T; Hirayama M; Fujikawa K; Shintani N; Mogi Y
    Jpn J Cancer Res; 1990 Jan; 81(1):91-9. PubMed ID: 2139019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunoassay of neocarzinostatin, an antitumor protein.
    Samy TS; Raso V
    Cancer Res; 1976 Dec; 36(12):4378-81. PubMed ID: 63321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery.
    Maeda H; Sano Y; Takeshita J; Iwai Z; Kosaka H; Marubayashi T; Matsukado Y
    Cancer Chemother Pharmacol; 1981; 5(4):243-9. PubMed ID: 6455212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioimmunoassays for methotrexate, citrovorum factor, neocarzinostatin, and actinomycin D.
    Raso V
    Cancer Treat Rep; 1977 Jul; 61(4):585-90. PubMed ID: 141980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeting effect of transferrin-neocarzinostatin conjugate by receptor-mediated endocytosis].
    Urushizaki I
    Nihon Rinsho; 1989 Jun; 47(6):1423-31. PubMed ID: 2528008
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of light and oxygen on neocarzinostatin stability and DNA-cleaving activity.
    Burger RM; Peisach J; Horwitz SB
    J Biol Chem; 1978 Jul; 253(14):4830-2. PubMed ID: 149790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neocarzinostatin: report of a phase II clinical trial.
    McKelvey EM; Murphy W; Zander A; Bodey GP
    Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neocarzinostatin abstracts a hydrogen during formation of nucleotide 5'-aldehyde on DNA.
    Charnas RL; Goldberg IH
    Biochem Biophys Res Commun; 1984 Jul; 122(2):642-8. PubMed ID: 6235811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
    McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
    Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neocarzinostatin: controlled release of chromophore and its interaction with DNA.
    Jung G; Köhnlein W
    Biochem Biophys Res Commun; 1981 Jan; 98(1):176-83. PubMed ID: 6452126
    [No Abstract]   [Full Text] [Related]  

  • 40. The mechanism of the neocarzinostatin-induced cleavage of DNA.
    Sim SK; Lown JW
    Biochem Biophys Res Commun; 1978 Mar; 81(1):99-105. PubMed ID: 148890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.